Abstract: Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Abstract: A compound of the formula ##STR1## where R.sup.1 is the radical of the formula II or III ##STR2## is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV ##STR3## is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.

Abstract: 2-Cyano-3,5-dihydroxyhex-2-enecarboxamide derivatives ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of diseases or dissorders whose course involves increased connective tissue or cartilage degradation.

Abstract: The compound of the formula I or II ##STR1## is suitable for the production of a pharmaceutical for the treatment of carcinomatous disorders, where R.sup.1 is (C.sub.3 -C.sub.5)-cycloalkyl, (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl, R.sup.2 is CF.sub.3, OCF.sub.3, SCF.sub.3, OH, NO.sub.2, halogen, benzyl, phenyl, CN or O-phenyl, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, halogen or a hydrogen atom and X is a --CH group or a nitrogen atom.

Abstract: A compound of the formula ##STR1## where R.sup.1 is the radical of the formula II or III ##STR2## is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV ##STR3## is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.

Abstract: The use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disordersThe compound of the formula I or II ##STR1## is suitable for the production of a pharmaceutical for the treatment of carcinomatous disorders, where R.sup.1 is (C.sub.3 -C.sub.5)-cycloalkyl, (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl, R.sup.2 is CF.sub.3, OCF.sub.3, SCF.sub.3, OH, NO.sub.2, halogen, benzyl, phenyl, CN or O-phenyl, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, halogen or a hydrogen atom and X is a --CH group or a nitrogen atom.

Abstract: A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R.sup.1 or R.sup.2 stands for the formula (II), are suitable for preparing medicaments for the therapy of inflammations, asthma, rheumatoid diseases and auto-immune diseases.

Abstract: A casting chamber has a casting plunger guided therein. In order to supply the casting plunger with lubricant on its outer circumferential surface, the casting chamber has a lubricant channel which runs round in a ring and is supplied via a feed line with lubricant which, after flowing through the lubricant channel, passes into a discharge line for the lubricant.

Abstract: Compounds of the formula (I) ##STR1## and their use as antidotes against the phytotoxicity of many herbicides used on crops, without diminishing the effect of the herbicide against weeds.

Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of ##STR2## R.sub.13, R.sub.14 and R.sub.15 are individually selected from the group consisting of hydrogen, halogen and alkyl of 1 to 3 carbon atoms, n is an integer from 1 to 3, R.sub.2 is hydrogen or alkyl of 1 to 3 carbon atoms, R.sub.3, R.sub.4 R.sub.5, R.sub.6 and R.sub.7 are individually selected from the group consisting of hydrogen, halogen, --NO.sub.2, --CN, alkyl, alkylthio and alkoxy of 1 to 6 carbon atoms, alkylcarbonyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, ##STR3## m is 0, 1, 2 or 3, n is 1, 2 or 3; Hal, Hal.sub.1, Hal.sub.2 and Hal.sub.3 are individually halogen and ##STR4## R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are individually any of the groups defined above for R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 or R.sub.4 and R.sub.5 together form --O--CH.sub.

Abstract: Novel 3,5-disubstituted 2-isoxazolines and isoxazoles and novel pharmaceuticals are described which are suitable, in particular, for the prophylaxis and/or treatment of pathological, neurodegenerative disorders in humans and animals. Processes for the preparation of these 3,5-disubstituted 2-isoxazolines and isoxazolines and isoxazoles are additionally indicated.

Abstract: In a die-casting machine for producing castings from metals or metal alloys, which castings have a low content of gas, pores and oxides, melt is drawn by means of a vacuum out of a holding device (10) via a suction tube (11) into a casting chamber (3). A casting plunger (7) closes the inlet opening (16) to the casting chamber (3). In order to achieve as low as possible mechanical surface pressure due to flow of the melt, and fluviatile erosion of the die-side end of the inlet opening (16), and thus avoid high wear of this inlet edge or of the casting chamber with casting plunger, a planar or linear inlet cross-section (24, 27) as well as a curved deflection surface (20) on the casting plunger (7) are provided.

Abstract: Pharmaceuticals containing or composed of at least one compound of the formula I and/or one of its physiologically tolerated salts where appropriate, where the compounds of the formula I can, where appropriate, be in the form of pure stereoisomers or mixtures thereof; formula I is: ##STR1## in which R.sup.1 =organic radical or halogen,A=C,C single or C,C double bond,n=0, 1 or 2, and ##STR2## R.sup.2 and R.sup.3 =H or optionally substituted aliphatic radical. The pharmaceuticals are suitable for the prophylaxis and/or treatment of diseases of the immune system, especially of tumors, infections and/or autoimmune diseases of the human or animal body and for use as adjuvants for vaccines.Some of the compounds of the formula I are new; the compounds can be prepared by special processes.

Abstract: Cesium chloride is recovered from used density gradient solutions by extraction of lipophilic and coloring components using a lipophilic solvent, subsequent extraction with a polar protic organic solvent, adding perchlorate ions to the extraction residue, and converting the precipitated cesium perchlorate into cesium chloride.

Abstract: Process for the preparation of cephem compounds of the formula ##STR1## wherein R is optionally substituted aminothiazolyl or amino-1,2,4-thiadiazolyl, A is optionally substituted pyridinium, R.sup.1 is hydrogen or methoxy and R.sup.2 are special aliphatic substituents, by a nucleophilic replacement in the substituent in 3-position in the presence of tri-C.sub.1 C.sub.4 -alkyl iodosilane.

Abstract: Process for the preparation of cephem compounds of the formula ##STR1##

Abstract: The invention relates to cephem derivatives of the general formula I ##STR1## and their physiologically acceptable acid addition salts, to pharmaceutical formulations active against bacterial infections, to processes for preparing the compounds and formulations, and to the use of the compounds for combating bacterial infections.

Abstract: A diecasting process for producing cast pieces for metals or their alloys by means of a horizontal cold chamber diecasting machine. The diecasting machine includes a diecasting mold held under a vacuum, a fill chamber coupled to the diecasting mold, a holding furnace containing metal melt, a suction pipe partially immersed in the holding furnace and coupled to the fill chamber, means for transporting metal melt from the holding furnace through the suction pipe into the fill chamber under a vacuum, and means for moving the metal melt from the fill chamber into the diecasting mold. During the dosaging phase when the fill chamber is filled with metal melt, gases and lubricant vapors are developed upon entry of the melt into the fill chamber.